European Society of Cardiology (ESC) Congress 2025
Madrid, Spain 29 August 2025 - 01 September 2025
Boosting potassium wards off ventricular arrhythmias in patients with ICD
Increasing low potassium levels improves clinical outcomes in patients with cardiovascular disease (CVD) and a high risk for ventricular arrhythmias, as shown in the POTCAST trial presented at ESC 2025.
Old cardio drug pulls a surprise in DIGIT-HF trial
Adding the cardiac glycoside digitoxin to guideline-directed medical therapy (GDMT) improves clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF), as shown in the DIGIT-HF trial, which took over 10 years to complete due to funding constraints.
Semaglutide, dulaglutide help prevent cognitive decline in HF patients
Treatment with semaglutide and dulaglutide results in a significantly lower risk of adverse cognitive decline in patients with heart failure (HF), as shown by the results of a retrospective cohort study using real-world data.
Add-on baxdrostat shows promise for hard-to-control BP
In the phase III BaxHTN trial, the highly selective and potent aldosterone synthase inhibitor baxdrostat efficiently controls blood pressure (BP) when added to background antihypertensive therapy for the treatment of uncontrolled or treatment-resistant hypertension (HTN).
Amlodipine-telmisartan-chlorthalidone combo promises better BP-lowering effect
A low-dose combination therapy, AD-209, that includes telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 6.25 mg demonstrates efficacy in lowering high blood pressure (BP) when compared with telmisartan alone in patients with essential hypertension, reports a study presented at ESC 2025.
